Ovid Therapeutics (United States)

InstitutionResearch output, impact & collaborations

Ovid Therapeutics (United States) is a institution indexed in ScholarIQ from OpenAlex.

What is known about Ovid Therapeutics (United States)?

ScholarIQrecord summary

Ovid Therapeutics (United States) is a research organisation in New York, United States. OpenAlex records 99 works and 2,280 citations for it. 1 researchers list it as their most recent affiliation.

How many works does Ovid Therapeutics (United States) have?

ScholarIQindexed works

Ovid Therapeutics (United States) has 99 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

See the works listed for Ovid Therapeutics (United States) →

How many citations does Ovid Therapeutics (United States) have?

ScholarIQcitation count

Ovid Therapeutics (United States) has 2,280 citations in the OpenAlex counts ScholarIQ stores.

See the listed works for Ovid Therapeutics (United States) →

How many researchers are at Ovid Therapeutics (United States)?

ScholarIQresearcher count

Ovid Therapeutics (United States) has 1 researchers in the ScholarIQ index.

See the researchers listed on this page →

What is the average h-index at Ovid Therapeutics (United States)?

ScholarIQavg h-index

Ovid Therapeutics (United States) has an average h-index of 74 in OpenAlex.

Open the OpenAlex record →

What is the ROR of Ovid Therapeutics (United States)?

ScholarIQror

The ROR for Ovid Therapeutics (United States) is on the source record.

Open the ROR →

What is the OpenAlex record for Ovid Therapeutics (United States)?

ScholarIQopenalex

The OpenAlex for Ovid Therapeutics (United States) is on the source record.

Open the OpenAlex →

Who are the most-cited researchers behind Ovid Therapeutics (United States)?

ScholarIQtop researchers by citations

Matthew J. During · Neuroscience and Neuropharmacology Research

217 works21,591 citations

What are the most-cited papers on Ovid Therapeutics (United States)?

ScholarIQmost cited works

Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial

Michael G. Kaplitt, Andrew Feigin, Chengke Tang, Helen L. Fitzsimons, Paul J. Mattis, P. Lawlor, Ross Bland, Deborah Young, Kristin Strybing, David Eidelberg, Matthew J. During

The Lancet. 20071,072 Citations

AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial

Peter A. LeWitt, Ali R. Rezai, Maureen A. Leehey, Steven Ojemann, Alice W. Flaherty, Emad N. Eskandar, Sandra K. Kostyk, Karen Thomas, Atom Sarkar, Mustafa Siddiqui, Stephen B. Tatter, Jason M. Schwalb, Kathleen L. Poston, Jaimie M. Henderson, Roger Kurlan, Irene Hegeman Richard, Lori Van Meter, Christine V. Sapan, Matthew J. During, Michael G. Kaplitt, Andrew Feigin

The Lancet Neurology. 2011675 Citations

How much of the research on Ovid Therapeutics (United States) is open access?

ScholarIQopen access share

0%OPEN ACCESS

Gold

Green

Hybrid

Bronze

Closed

100%